CLDN18 and neoplasm: The MONO trial was a phase II trial that assessed zolbetuximab monotherapy in 54 patients with recurrent or refractory advanced GC or lower esophageal adenocarcinoma (EAC) exhibiting moderate-to-strong CLDN18.2 expression in ≥50% of tumor cells.